Safety and pharmacokinetics of veliparib extended‐release in patients with advanced solid tumors: a phase I study

por Werner, Theresa L., Sachdev, Jasgit, Swisher, Elizabeth M., Gutierrez, Martin, Kittaneh, Muaiad, Stein, Mark N., Xiong, Hao, Dunbar, Martin, Sullivan, Danielle, Komarnitsky, Philip, McKee, Mark, Tan, Antoinette R.
Publicado 2018

A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors

por Connor, Joseph P, Cristea, Mihaela C, Lewis, Nancy L, Lewis, Lionel D, Komarnitsky, Philip B, Mattiacci, Maria R, Felder, Mildred, Stewart, Sarah, Harter, Josephine, Henslee-Downey, Jean, Kramer, Daniel, Neugebauer, Roland, Stupp, Roger
Publicado 2013

A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours

por Berlin, Jordan, Ramanathan, Ramesh K., Strickler, John H., Subramaniam, Deepa S., Marshall, John, Kang, Yoon-Koo, Hetman, Robert, Dudley, Matthew W., Zeng, Jiewei, Nickner, Caroline, Xiong, Hao, Komarnitsky, Philip, Shepherd, Stacie Peacock, Hurwitz, Herbert, Lenz, Heinz-Josef
Publicado 2018

Phase 1 dose‐escalation study of single‐agent veliparib in Japanese patients with advanced solid tumors

por Nishikawa, Tadaaki, Matsumoto, Koji, Tamura, Kenji, Yoshida, Hiroyuki, Imai, Yuichi, Miyasaka, Aki, Onoe, Takuma, Yamaguchi, Satoshi, Shimizu, Chikako, Yonemori, Kan, Shimoi, Tatsunori, Yunokawa, Mayu, Xiong, Hao, Nuthalapati, Silpa, Hashiba, Hideyuki, Kiriyama, Tsukasa, Leahy, Terri, Komarnitsky, Philip, Fujiwara, Keiichi
Publicado 2017

Phase 1 study of veliparib with carboplatin and weekly paclitaxel in Japanese patients with newly diagnosed ovarian cancer

por Nishio, Shin, Takekuma, Munetaka, Takeuchi, Satoshi, Kawano, Kouichirou, Tsuda, Naotake, Tasaki, Kazuto, Takahashi, Nobutaka, Abe, Masakazu, Tanaka, Aki, Nagasawa, Takayuki, Shoji, Tadahiro, Xiong, Hao, Nuthalapati, Silpa, Leahy, Terri, Hashiba, Hideyuki, Kiriyama, Tsukasa, Komarnitsky, Philip, Hirashima, Yasuyuki, Ushijima, Kimio
Publicado 2017

Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non–Small Cell Lung Carcinoma

por Camidge, D. Ross, Morgensztern, Daniel, Heist, Rebecca S., Barve, Minal, Vokes, Everett, Goldman, Jonathan W., Hong, David S., Bauer, Todd M., Strickler, John H., Angevin, Eric, Motwani, Monica, Parikh, Apurvasena, Sun, Zhaowen, Bach, Bruce Allen, Wu, Jun, Komarnitsky, Philip B., Kelly, Karen
Publicado 2021